When the infliximab and placebo treatment groups were combined , patients with at least 75 % improvement in PASI scores between baseline and week 10 had a greater mean improvement in DLQI scores ( 81 % ) than those with 50-75 % improvement in PASI during the same period ( 60 % ) .
